The impact of Empagliflozin on chronic kidney disease patient regardless of diabetes: A review

Josina Joseph; Devika Dinesh; Chintha Chandran; Drishya L; Shaiju S Dharan

The impact of Empagliflozin on chronic kidney disease patient regardless of diabetes: A review

Asian Journal of Pharmaceutical and Health Sciences,2025,14,4,3036-3040.

DOI:10.5530/ajphs.2024.14.72

Published:June 2025

Type:Research Article

Authors:

Author(s) affiliations:

Josina Joseph¹, Devika Dinesh^1* , Chintha Chandran² , Drishya L ⁴, Shaiju S Dharan³

¹Pharm D Intern, Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India.

²Corresponding author, Assistant Professor, Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India.

³Associate Professor, Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India.

⁴HOD, Principal, Department of Pharmacy Practice, Ezhuthachan College of Pharmaceutical Sciences, Marayamuttom, Thiruvananthapuram, Kerala, India.

Abstract:

Empagliflozin usually considered as an antidiabetic medication but it shows other beneficial effects like reducing the mortality rate of heart failure patients with reduced ejection fraction and nephroprotective effect. Recent studies revealed that the drug decline the incidence of renal events, including death from renal causes, as well as the risk of end stage renal failure regardless of Type II Diabetes Mellitus. Clinical trial related Empagliflozin on CKD patient confirmed that it has a consistent effect on the disease progression. This review aim to analysing the impact of Empagliflozin on Chronic Kidney Disease patient regardless of Diabetes.

Keywords:CKD, Empagliflozin, Nephroprotective effect., SGLT2, Type II Diabetes Mellitus